Lesofavumab
Based on 1 Customer Validation
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.27%
- CAS. Nr.: 1807960-57-1
- Molecular Weight:147.08 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
influenza A virus hemagglutinin HA
In Vitro
Lesofavumab (MHAB5553A) binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA), a major immunodominant surface glycoprotein on influenza B viruses, and blocks HA-mediated membrane fusion in the endosome[1].
Lesofavumab (46B8) is able to neutralize all eleven IBV strains tested that were associated with human infections spanning >70 years, with IC50 values ranging from 0.58 to 0.95 nM[2].
Lesofavumab (46B8; 0-100 ng/mL) blocks membrane fusion and induces antibody-dependent cellular cytotoxicity (ADCC) in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/2 J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2]
-
Dosage:15 mg/kg
-
Administration:Intravenous administration, single dose, 24, 48 or 72 h post infection
-
Result:Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48 h. Even when given at 72 h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 1807960-57-1
-
Appearance Liquid
-
Molecular Weight 147.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Lesofavumab]
-
Synonyms
MHAB5553A; RG70026
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421. [Content Brief]
[2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Lesofavumab Related Classifications
HY-P99699 Related Classifications
Powered by Bioz